AI native CRM for the next generation of teams

Powerful, flexible, and intuitive to use, Attio is the CRM for the next-generation of teams.

Sync your email and calendar, and Attio instantly builds your CRM—enriching every company, contact, and interaction with actionable insights in seconds.

Join fast growing teams like Flatfile, Replicate, Modal, and more.

Start for free today.

Abbott Laboratories DCF Stock Analysis

Here’s my assumptions:

Risk Free Rate (10 Years Interest Rate Swap): 4.1%

Risk Premium (Taken from the Aswath Damodaran equity premium spreadsheet): 4.33%

Interest Rate Spread on The Risk free rate ( For the cost of debt calculation): 1.5%

Historical Data

Revenue growth in the last 10 years (CAGR): 7.47%

Earnings growth in the last 10 years (CAGR): 11.72%

Unlevered Free Cash Flow growth in the last 10 years (CAGR): 5.31%

Future Assumptions

End of Year FCF growth: 3%

Growth until end of 2026: 5%

Growth until end of 2034: 4%

Perpetual growth: 3%

Net Debt: 6.446B

Outstanding Stock Options Present Value Assumption: $1.202B

Restricted Stock Units Present Value Assumption: $1.321B

Stock Valuation based on these assumptions: $138

Last update 08/01/2025

All the content in this newsletter should be taken as informational content only. THIS IS NOT FINANCIAL ADVICE! Do your own Due Diligence before investing or contact a professional financial advisor.

I don’t have a position in Abbott Laboratories (ABT) and I don’t plan to add a position in the coming days.